Maria S.

Maria S. has over 15 years of experience in translational sciences and oncology. Maria began their career in 2006 as a Ph.D. at the DKFZ German Cancer Research Center in the Department of Molecular Genetics. During their tenure, they conducted high throughput gain and loss function cell-based assays, identifying novel genes involved in cell proliferation and apoptosis. In 2010, they became a Postdoctoral Fellow at the MD Anderson Cancer Center in the Department of Systems Biology. During this role, they engaged in analysis of Pan-Cancer proteomic data of TCGA cancer patients, identifying novel molecular stratification of different types of cancers, as well as coordinated pathway analysis. In 2014, they became a Postdoctoral Fellow at Ionis Pharmaceuticals, Inc. in the Department of Functional Genomics. Maria coordinated the implementation of Antisense Oligonucleotide (ASO) as a therapeutic technique, targeting malignant cells and successfully showed Antisense oligonucleotides targeting ENO2 have selective anti-proliferative effects in Glioblastoma Cells with 1p36 genomic loss both in vitro and in vivo. In 2016, they became a Biology Scientist at Avidity Biosciences, Inc. where they led targeted therapy for immune system diseases and cancer incorporating Antibody-siRNA Conjugates (ASC) as a therapeutic approach leading to agreement between Eli Lilly company and Avidity Biosciences. In 2019, they became a Translational Oncology at Mitsubishi Tanabe Reseach laboratories. Currently, they are a Principal Investigator, Translational Sciences at Adcentrx Therapeutics.

Maria S. is currently enrolled at Saarland University & German Cancer Research Center. Additionally, they have obtained a Leadership & Innovation certification from MIT Professional Education in September 2021.